Studies Investigating Predictive Ability of End-of-Treatment PET Imaging in HL
| Results | ||||
| Study | Patient population | Treatment regimen | PET+ | PET− |
| Spaepen, 2001 (68) | 60 HL patients (25 limited, 35 advanced) | Stanford V, MOPP/ABV | 2-y PFS: 0% | 2-y PFS: 91% |
| Weihrauch, 2001 (69) | 28 HL patients (10 limited, 18 advanced/relapsed) | Nonuniform | 1-y DFS: 40% | 1-y DFS: 95% |
| Kobe, 2008 (70) | 817 bulky/advanced-HL patients | 6–8 cycles (BEACOPP) | 2-y PFS: 86% | 2-y PFS: 96% |
| Barnes, 2011 (15) | 96 limited-HL patients | 4 cycles (ABVD) | 4-y PFS: 54% | 4-y PFS: 94% |
| Kobe, 2014 (21) | 739 advanced-HL patients | 6–8 cycles (BEACOPP) | 4-y PFS: 86.1% | 4-y PFS: 91.5% |
MOPP/ABV = mechlorethamine, vincristine, procarbazine, prednisone, adriamycin, bleomycin, and vinblastine; DFS = disease-free survival.